Supplementary Table 1 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392848

2023-01-01

Abstract:PDF file - 64K, MSC-L can exert therapeutic effect to inhibit tumor growth and induce immune

What problem does this paper attempt to address?

Supplementary Figure 5 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392863.v1

2023-01-01

Abstract:PDF file - 2.0MB, MSC-L did not mainly impact on tumor proliferation, apoptosis and angiogenesis
Supplementary Figure 2 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392872.v1

2023-01-01

Abstract:PDF file - 2MB, MSC, MSC-mock, and MSC-L have similar infiltration pattern in tumor tissues
Supplementary Figure 1 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392875.v1

2023-01-01

Abstract:PDF file - 1.2MB, MSC-L mainly located in tumor tissues and could express LIGHT in tumor
Supplementary Figure 7 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392857.v1

2023-01-01

Abstract:PDF file - 1.9MB, MSC-L trafficking in vivo in earlier time point
Supplementary Figure 4 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392866.v1

2023-01-01

Abstract:PDF file - 1.8MB, MSC-L enhanced inflammation reaction in tumor tissues
Supplementary Figure 6 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392860.v1

2023-01-01

Abstract:PDF file - 1.3MB, Detection of I-Ad on MSC-L
Supplementary Figure 8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392854.v1

2023-01-01

Abstract:PDF file - 1.5MB, Matrigel plugs migration assay in prophylactic setting
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Figure 3 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392869.v1

2023-01-01

Abstract:PDF file - 1.8MB, Transfection with retroviral vector without LIGHT did not protect the host against tumor
Supplementary Figure Legends 1-8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392851.v1

2023-01-01

Abstract:PDF file - 164K
Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Yigiang Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481007.v1

2023-01-01

Abstract:Supplemental Table 1: Flow Cytometry Antibodies
Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Ping Lu,Chao Ge,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395144.v1

2023-01-01

Abstract:PDF file - 82K, Antibodies used in this study
Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Peixiang Lu,Ge Chen,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395141

2023-01-01

Abstract:PDF file - 47K, Sequences of primers used in this study
Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503678.v1

2023-01-01

Abstract:PDF - 64K, Supplementary Table 3. Minimum Inhibitory Concentrations* of BMS-777607 and Chemoagents in L3.6pl Cells and L3.6pl Cell-Derived CSCs+24/44/ESA.
Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503681

2023-01-01

Abstract:PDF - 79K, Supplementary Table 2. Sensitivities of L3.6pl cells, CSCs+24/44/ESA and their derived polyploid cells in response to different chemotherapeutics.
Supplementary Figures 1 - 7 from Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment

Weifang Ling,Jimin Zhang,Zengrong Yuan,Guangwen Ren,Liying Zhang,Xiaodong Chen,Arnold B. Rabson,Arthur I. Roberts,Ying Wang,Yufang Shi

DOI: https://doi.org/10.1158/0008-5472.22400901

2023-01-01

Abstract:PDF file - 794KB, Immunosuppressive effect of another constitutive IDO-expressing MSC clone MSC-IDOc2 (S1); Expression of iNOS or IDO in MSCs upon cytokine stimulation and their effect on lymphocyte proliferation (S2); Effect of iNOS-/- MSCs on proliferation of activated human peripheral blood mononuclear cells (S3); In Situ expression and location of human IDO in the tumor tissue (S4); Effect of IDO-expressing MSCs on the distribution of immune cell subpopulations in peripheral blood and tumor tissues (S5); Effect of IDO-expressing MSCs on the distribution of immune cell subpopulations in peripheral blood and tumor tissues (S6); Effect of IDO-expressing MSCs on the distribution of immune cell subpopulations in peripheral blood and tumor tissues (S7).
Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399947.v1

2023-01-01

Abstract:PDF file - 31KB, Supplementary Figure 2 Determination of concentration of IL-6 and IL-10 within tumor.
Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399923.v1

2023-01-01

Abstract:PDF file - 71KB, Supplementary Table 1 Characteristics of 7 types of cancer patient in cancer survey array. Supplementary Table 2 Characteristics of patient in melanoma RNA chip. Supplementary Table 3 Characteristics of patient in melanoma IHC chip. Supplementary Table 4. Characteristics of patient in flow cytometry analysis.
Mesenchymal Stem Cells-Based Targeting Delivery System: Therapeutic Promises and Immunomodulation against Tumor

Tianyuan Zhang,Ting Huang,Yuanqin Su,Jianqing Gao

DOI: https://doi.org/10.1002/adtp.202100030

IF: 5.003

2021-01-01

Advanced Therapeutics

Abstract:The inherent homing ability toward tumor sites of mesenchymal stem cells (MSCs) after systemic delivery has, during the past decade, created an impetus to develop these stem cells as living carriers for successful tumor-targeted therapy. Nevertheless, the controversies about the role of MSCs in promoting or inhibiting tumor progress are impeding the potential clinical application ofthis system, which is partly due to the contradictory immunomodulation capability. Therefore, in this review, updated progress in the applications of MSCs as the cellular carrier for tumor-targeting therapy, are summarized. In addition, the immunomodulating capability of MSCs and its influences on tumor progress and metastasis are highlighted. Finally, the advantages and potential risks of MSCs concerning their modulation of immune responses and the factors determining their immune properties are emphasized. It is hoped that the challenges surrounding the impacts on immune response induced by the administration of MSCs summarized in this review will provide a critical guidance for the rational design and proper application of MSCs-based targeting delivery system for tumor therapy.

Supplementary Table 1 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 5 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 2 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 1 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 7 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 4 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 6 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Figure 3 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure Legends 1-8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133&lt;sup&gt;+&lt;/sup&gt; Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figures 1 - 7 from Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Mesenchymal Stem Cells-Based Targeting Delivery System: Therapeutic Promises and Immunomodulation against Tumor

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma